Reumatologia最新文献

{"title":"Serum levels of tumor necrosis factor-like cytokine 1A and its receptors, death receptor 3 and decoy receptor 3, in patients with spondyloarthropathies: preliminary results from a cross-sectional study.","authors":"Emilia Anna Frąckiel, Adrianna Błahuszewska-Omyła, Paweł Bielecki, Magdalena Bagrowska, Natalia Szymańska, Krzysztof Kowal, Otylia Kowal-Bielecka","doi":"10.5114/reum/203129","DOIUrl":"10.5114/reum/203129","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a member of the TNF superfamily of cytokines, involved in regulation of the immune and inflammatory response. Recently, therapies aimed at blockade of the TL1A pathway have shown benefit in the treatment of inflammatory bowel diseases (IBDs). However, very little is known regarding activation of the TL1A axis in spondyloarthropathies (SpA), which are clinically and pathogenetically linked to IBDs. Our study investigated soluble forms of TL1A and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3), in the serum of patients with SpA, and evaluated potential associations between concentrations of the investigated molecules and clinical features of SpA.</p><p><strong>Material and methods: </strong>Tumor necrosis factor-like cytokine 1A, DR3, and DcR3 concentrations were measured (using enzyme linked immunosorbent assay - ELISA) in the serum of 82 patients with SpA and 36 healthy controls.</p><p><strong>Results: </strong>We found no significant difference in serum concentrations of TL1A or DR3 between the study and the control groups. However, we observed a significantly higher concentration of DcR3 (median [min.-max.]: 292.31 [93.241-13,862.10] pg/ml) in patients with SpA than in the controls (median [min.-max.]: 126.73 [10.68-1,482.74] pg/ml; <i>p</i> = 0.003). The DR/DcR ratio was significantly lower in patients with SpA (median [min.-max.]: 4.05 [0.14-235.39]) than in the controls (17.22 [0.00-750.66]; <i>p</i> = 0.002). Moreover, there were weak but significant correlations between serum concentrations of DcR and TL1A (Spearman's rho: 0.28, <i>p</i> < 0.05) and between DcR3 and C-reactive protein as well as erythrocyte sedimentation rate values (Spearman's rho: 0.25 and 0.24 respectively, <i>p</i> < 0.05 for both) in patients with SpA.</p><p><strong>Conclusions: </strong>The results of our study indicate that the TL1A/DR3/DcR3 axis is activated in patients with SpA and may represent a new target for therapies in this group of diseases. Further studies are needed to confirm our data.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"216-221"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern diagnostics for dry eye disease: implications for rheumatology.","authors":"Adam Wylęgała","doi":"10.5114/reum/209449","DOIUrl":"10.5114/reum/209449","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"213-215"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiotherapy management strategies for chronic pain control in patients with lumbosacral transitional vertebrae and low back pain: a review of the literature.","authors":"Justyna Frasuńska, Barbara Stypińska, Beata Tarnacka","doi":"10.5114/reum/202295","DOIUrl":"10.5114/reum/202295","url":null,"abstract":"<p><p>Physiotherapy is a widely used form of treatment of low back pain (LBP) and is important in non-surgical/surgical management of patients with lumbosacral transitional vertebrae (LSTV). This review presents physiotherapeutic management in LSTV patients with LBP. A search was performed in PubMed, Scopus, Embase, Medline, and Google Scholar between November 20 and December 31, 2023. The mean age of patients was 39 years. The patients had an average of 13 sessions, and the average duration of physiotherapy was 3 weeks (frequency of 1-5 sessions/week). The physiotherapy methods used were: manual therapy, mobility training, motor control training, myofascial approach and hot packs, and electrotherapy. Outcome measures were pain scales, range of motion testing, improvement in sleep, return to work, physical activity, or muscle thickness. The reviewed papers described pain reduction, though pain recurrence occurred with varying frequency (1-3 months after therapy). Physiotherapy for LSTV patients should be a first-line treatment, but requires an individualized approach.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"251-265"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-interferon α-antibodies in pediatric patients with COVID-19 and long COVID.","authors":"Oksana Boyarchuk, Vita Perestiuk, Tetiana Kosovska, Liubov Volianska","doi":"10.5114/reum/204365","DOIUrl":"10.5114/reum/204365","url":null,"abstract":"<p><strong>Introduction: </strong>The involvement of neutralizing antibodies against type I interferon (IFN-I) in the development of severe coronavirus disease 2019 (COVID-19) in adult patients has been well documented. However, the role of anti-IFN-α autoantibodies, especially non-neutralizing types, remains underexplored, especially in children. Our study aimed to determine the frequency of antibodies against IFN-α in children with COVID-19 and long COVID, as well as their potential role in the development of long COVID.</p><p><strong>Material and methods: </strong>The study included 78 children aged 1 to 17 years with a documented history of COVID-19 from September 2022 to August 2023. All patients were divided into three groups: hospitalized with COVID-19, hospitalized with long COVID symptoms, and monitored in an outpatient care department for mild COVID-19 or symptoms of long COVID. Human anti-IFN-α antibodies were detected using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Binding anti-IFN-α antibodies were detected in 2/78 (2.6%) children with COVID-19 of varying severity. One patient with anti-IFN-α antibodies had comorbidities (obesity, allergic rhinitis) and critical COVID-19 pneumonia (SpO₂ - 80%), significant inflammatory changes (neutrophil-to-lymphocyte ratio: 18.8, C-reactive protein: 95.5 mg/l), and a high D-dimer level, and later developed long COVID symptoms. In the second case, COVID-19 in a 13-year-old girl without significant comorbidities was not severe, but leukopenia and lymphopenia were observed. Subsequently, she developed pronounced long COVID symptoms (fatigue, reduced appetite, insomnia, headache, decreased attention, difficulty concentrating, weight loss, tachycardia, dizziness), which persisted for up to 6 months after the acute infection. The detection rate of binding anti-IFN-α antibodies among hospitalized COVID-19 patients was 4%, compared to 25% among patients with severe/critical disease. Among children who developed long COVID symptoms, anti-IFN-α was found in 3.4%.</p><p><strong>Conclusions: </strong>Further studies in larger cohorts are needed to assess the role of anti-IFN-α antibodies (both neutralizing and non-neutralizing) in the development of long COVID symptoms, to understand their clinical significance, and to examine their dynamics over time.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"229-235"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?","authors":"Laila Taoubane, Abdellah El Maghraoui, Redouane Niamane, Ihsane Hmamouchi, Fadoua Allali, Rachid Bahiri, Ouafae Mkinsi, Hasna Hassikou, Imad Ghozlani, Bezza Ahmed","doi":"10.5114/reum/205366","DOIUrl":"10.5114/reum/205366","url":null,"abstract":"<p><strong>Introduction: </strong>The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors.</p><p><strong>Material and methods: </strong>We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by biological drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software.</p><p><strong>Results: </strong>We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 patients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1-144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex (<i>p</i> = 0.05) and to disease activity in patients with RA (<i>p</i> = 0.04).</p><p><strong>Conclusions: </strong>Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the management of our patients with chronic inflammatory rheumatism.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"244-250"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm.","authors":"Marco Tasso, Luisa Costa, Nicoletta Bertolini, Antonio Del Puente, Rosario Peluso, Alfonso Oriente, Francesca Foglia, Mario Cascone, Francesco Caso","doi":"10.5114/reum/207507","DOIUrl":"10.5114/reum/207507","url":null,"abstract":"<p><p>Janus kinase inhibitors (JAKi) are effective treatments for rheumatoid arthritis (RA), but growing evidence raises cardiovascular (CV) safety concerns. Given the elevated baseline CV risk in RA, appropriate risk stratification is essential. We retrospectively analyzed 116 RA patients treated with JAKi at the University of Naples Federico II (2020-2025), excluding those with previous CV events. Cardiovascular risk was assessed using the CUORE algorithm, adjusted with the European Alliance of Associations for Rheumatology-recommended 1.5 multiplication factor. Patients were stratified into low (37.9%), intermediate (48.3%), and high (13.8%) risk categories. Over a median follow-up of 25.6 months, only one major CV event (myocardial infarction) was recorded, with no CV deaths. Despite the algorithm being developed for the general population, it appears feasible for RA patients on JAKi. Our findings suggest its potential role in guiding CV prevention strategies, although larger, multicenter studies are needed to confirm its predictive value and integrate RA-specific variables.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"281-283"},"PeriodicalIF":1.7,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation and validation of Polish versions of the Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire.","authors":"Kinga Maria Tyczyńska, Piotr Krzysztof Krajewski, Daria Kuc, Piotr Krawiec, Piotr Wawryka, Adam Zalewski, Brygida Kwiatkowska, Jacek Cezary Szepietowski, Bogdan Piotr Batko","doi":"10.5114/reum/209210","DOIUrl":"10.5114/reum/209210","url":null,"abstract":"<p><strong>Introduction: </strong>Early detection of psoriatic arthritis (PsA) is critical to prevent joint damage and disability. The Psoriasis Epidemiology Screening Tool (PEST) and the Early Arthritis for Psoriatic Patients (EARP) questionnaire are established instruments for identifying PsA in patients with psoriasis. However, validated Polish versions were not available. This study aimed to translate and validate the Polish versions of both questionnaires.</p><p><strong>Material and methods: </strong>The translation process followed international guidelines. Two independent forward translations from English to Polish were performed by translators (P.K.K., K.M.T.), and a unified version was established by a third consultant (J.C.S.). This was followed by two independent back translations from Polish into English (A.Z., P.W.) to ensure accuracy. The back translations were presented to the authors of the original questionnaires. Cognitive debriefing was conducted with eight patients diagnosed with PsA to enhance clarity and cultural relevance. The final Polish questionnaires were then administered to 45 adult patients diagnosed with PsA, as defined by the Classification Criteria for Psoriatic Arthritis, who were recruited from three clinical centers. Participants completed the questionnaires twice within a 3-to-5-day interval. The obtained data were subjected to statistical analysis.</p><p><strong>Results: </strong>The Polish versions of PEST and EARP demonstrated adequate internal consistency, with Cronbach's α values of 0.712 for PEST and 0.771 for EARP. Test-retest reliability was robust, with intraclass correlation coefficient values of 0.731 and 0.730 for the respective questionnaires. No statistically significant differences were observed between the two assessments (<i>p</i> > 0.05). A limitation of this study is the absence of convergent validity, primarily due to the lack of other validated Polish screening instruments.</p><p><strong>Conclusions: </strong>The validated Polish versions of the PEST and the EARP questionnaires are reliable instruments for screening PsA. Their implementation in clinical practice may facilitate early diagnosis and referral to rheumatology, thereby enhancing patient management in Poland.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"236-243"},"PeriodicalIF":1.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct characteristics of carpal tunnel syndrome among Sjögren's disease patients and their clinical implications.","authors":"Iga Kościńska-Shukla, Marta Magdalena Jaskólska, Michał Chmielewski","doi":"10.5114/reum/201149","DOIUrl":"10.5114/reum/201149","url":null,"abstract":"<p><p>Carpal tunnel syndrome (CTS) is the most common entrapment syndrome, affecting 3-6% of the adult population. Its prevalence among patients with primary Sjögren's disease (pSjD) is much higher. Interestingly, clinical observations do not support the view that the incidence of CTS increases with joint involvement. Moreover, patients with pSjD oftentimes present worse outcomes of traditional therapeutic methods. Herein, we present two cases of patients with CTS in the course of pSjD. In one of them, there was rapid recurrence of symptoms after surgery, and in the other, delayed healing was observed. In this article, the authors highlight the diagnostic and therapeutic challenges encountered in daily practice, resulting from probable differences in the pathophysiology of nerve involvement in Sjögren's disease patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"274-280"},"PeriodicalIF":1.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystatin D as a biomarker for rheumatoid arthritis: relation to disease activity and joint damage.","authors":"Ola Mounir, Ahmed Sedky, Omar M Mohafez, Sahar A Elsayed","doi":"10.5114/reum/199871","DOIUrl":"10.5114/reum/199871","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is a multisystem autoimmune disorder. Autoantibody levels in the serum of RA patients can guide the diagnosis and treatment. Cystatin D is a known inhibitor of cathepsins involved in RA pathogenesis. We aimed to determine the value of cystatin D in RA patients and to explore the relation between cystatin D serum level and disease activity and joint damage.</p><p><strong>Material and methods: </strong>Seventy adult RA patients and 40 sex- and age-matched healthy controls were included in this study. The patients' clinical, demographic, and rheumatologic data were recorded. Disease activity was measured using the Disease Activity Score in 28 joints (DAS28). Laboratory tests comprising complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein, serum creatinine, alanine aminotransferase, aspartate aminotransferase, rheumatoid factor, anti-citrullinated protein antibodies, and serum cystatin D were measured. In addition, we used the modified Larsen score to evaluate radiologic joint damage.</p><p><strong>Results: </strong>Cystatin D was elevated in RA patients compared to the controls and was negatively correlated with ESR, DAS28, and Larsen scores. At a cutoff value of 3.64 ng/ml, cystatin D could differentiate RA patients from healthy controls with 81.4% sensitivity and 75% specificity (<i>p</i> < 0.001). At a cutoff value of 5.22 ng/ml, cystatin D showed a significant value (<i>p</i> = 0.007) for differentiating active RA patients from those in remission, with 69.2% sensitivity and 78.9% specificity.</p><p><strong>Conclusions: </strong>Cystatin D may be a valuable marker for RA with good sensitivity and specificity. Moreover, its negative correlation with the DAS28 and the Larsen score suggests that it may be a marker adding to the DAS28 for the follow-up of disease activity and prediction of radiological joint damage. However, further studies with large sample sizes and long follow-up periods are required.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"222-228"},"PeriodicalIF":1.7,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Castleman disease.","authors":"Janine Qasim, Karthik Ramasamy","doi":"10.5114/reum/205807","DOIUrl":"10.5114/reum/205807","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 3","pages":"141-143"},"PeriodicalIF":1.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}